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OBJECTIVES We sought to examine the role of diabetes mellitus in cardiogenic shock (CS) complicating
acute myocardial infarction (AMI) in the SHOCK Trial Registry.
BACKGROUND The characteristics, outcomes and optimal treatment of diabetic patients with CS compli-
cating AMI have not been well described.
METHODS Baseline characteristics, clinical and hemodynamic measures, treatment variables, shock
etiologies and comorbid conditions were compared for 379 diabetic and 784 nondiabetic
patients. Logistic regression was used to examine the association between diabetes and
in-hospital mortality, after adjustment for baseline differences.
RESULTS Diabetics were less likely than nondiabetics to undergo thrombolysis (28% vs. 37%; p 5
0.002) or attempted revascularization (40% vs. 49%; p 5 0.008). The survival benefit for
diabetics selected for percutaneous or surgical revascularization (55% vs. 19% without
revascularization) was similar to that for nondiabetics (59% vs. 25%). Overall unadjusted
in-hospital mortality was significantly higher for diabetics (67% vs. 58%; p 5 0.007), but
diabetes was only a borderline predictor of mortality after adjustment for baseline and
treatment differences (odds ratio for death, 1.36; 95% confidence interval, 1.00 to 1.84; p 5
0.051).
CONCLUSIONS Diabetics with CS complicating AMI have a higher-risk profile at baseline, but after
adjustment, diabetics have an in-hospital survival rate that is only marginally lower than that
of nondiabetics. Diabetics who undergo revascularization derive a survival benefit similar to
that of nondiabetics. (J Am Coll Cardiol 2000;36:1097–103) © 2000 by the American
College of Cardiology
Cardiogenic shock (CS) is the leading cause of in-hospital
mortality after acute myocardial infarction (AMI) (1,2).
Nonrandomized series have described better outcomes for
MI patients in shock who are selected for early revascular-
ization, whether alone (3–6) or after thrombolysis (7). More
recently, the international, prospective, randomized SHould
we emergently revascularize Occluded Coronaries for car-
diogenic shocK? (SHOCK) Trial (8–10) has shown that
early revascularization, with angioplasty or bypass surgery, is
an effective treatment strategy for these patients. Whether
this benefit extends to the population of patients with
diabetes and CS who were not involved in the randomized
trial but were included in the SHOCK Trial Registry is the
subject of this article.
Diabetes has been shown to be an independent risk factor
for short-term mortality after thrombolysis for AMI, but
not after primary angioplasty (11), in the presence or
absence of CS (12,13). In two registries of elective angio-
plasty, diabetes was an independent predictor of long-term
adverse events (14,15). Nonetheless, in subgroup analyses of
randomized trials, diabetics with MI have been shown to
derive a clinical benefit, similar to that of patients without
diabetes, from either thrombolysis or primary angioplasty
and a similar relative early advantage from primary angio-
plasty versus thrombolysis (13,16). The conflicting results
seen in the randomized and registry portions of the Bypass
Angioplasty Revascularization Investigation (BARI)
(17,18) may reflect selection bias and differences in patient
characteristics (including the degree of glycemic control)
among diabetics with multivessel disease who undergo
bypass versus angioplasty. Thus, the optimal revasculariza-
tion method for diabetics remains unknown.
This analysis describes the characteristics, outcomes and
treatment of diabetic patients with CS complicating AMI
who were prospectively enrolled in the SHOCK Trial
Registry (8). Logistic regression was used to examine the
association between diabetes and in-hospital mortality, after
adjustment for baseline and treatment differences.
METHODS
The SHOCK Trial Registry. The design of the SHOCK
Trial and SHOCK Trial Registry has been reported (8,9).
In brief, patients with suspected CS complicating AMI
were registered prospectively at 36 centers, from April 1993
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through August 1997. Patients who did not meet all trial
inclusion criteria, and patients who met any single exclusion
criterion, were included in the SHOCK Trial Registry. This
includes patients with other etiologies for CS, including
those with acute, severe mitral regurgitation (MR), ventric-
ular septal rupture (VSR), isolated right ventricular (RV)
failure, cardiac tamponade or rupture, prior severe valvular
heart disease, dilated cardiomyopathy, or hemorrhage. In
all, 1,190 patients were included in the Registry. Twenty-
seven patients had unknown diabetes status. The remaining
1,163 are the subject of this article. For comparison, the
outcome of diabetics in the randomized SHOCK Trial is
reported here as well (10).
Data collection. Study coordinators abstracted data from
medical records and recorded them on standardized case-
report forms. The forms captured patient and infarct char-
acteristics, hemodynamic measures, procedure-use data and
vital status at discharge. Angiographic reports were sent to
the Clinical Coordinating Center for abstraction of data and
central completion of a standardized form (19). Height,
weight, blood urea nitrogen (BUN), creatinine, left ventric-
ular (LV) ejection fraction and presence of peripheral
vascular disease and of hyperlipidemia were collected on
approximately two thirds of patients.
Definitions. Patients were classified as diabetic if this
condition was checked on the case report form. The subtype
of diabetes was not routinely collected. The etiology of
shock was identified as isolated RV failure; acute, severe
MR; VSR; tamponade or LV rupture; prior severe valvular
heart disease; or predominant LV failure (if other major
shock categories did not apply) or iatrogenic shock. Recur-
rent ischemia was defined as rest angina or ischemic
symptoms $5 min with ST-segment depression, T-wave
inversion, or both with no cardiac enzyme elevation. Rein-
farction was defined as: 1) recurrent chest pain or ischemic
symptoms $30 min and recurrent ST-segment elevation,
new Q waves or new left bundle-branch block; 2) total
creatine kinase (CK) at least twice the upper limit of normal
and .25% or 200 U/mL over the previous value, with an
elevated CK-MB level; or 3) a rise in CK-MB above the
upper limit of normal after it had reverted to the normal
range. Only in-hospital survival was assessed.
Statistics. Baseline characteristics, clinical and hemody-
namic measures, shock etiologies and treatment variables
were summarized (for diabetics and nondiabetics) as means
and standard deviations for continuous variables and as
percentages for categorical variables. Skewed continuous
variables were presented as medians and interquartile
ranges. Groups were compared using the Fisher exact test
for categorical variables, the Mantel-Haenszel test for linear
trend for number of diseased vessels, and the Student t-test
or Wilcoxon rank-sum test for continuous variables. We
examined the independent association between diabetes and
in-hospital mortality with three logistic-regression models,
which were constructed by including all variables with a
univariate p-value for group comparison of #0.20. The first
model adjusted for patient characteristics only, while the
second model included both patient and treatment variables.
We also explored the possibility of an interactive effect
between diabetes and angioplasty or bypass surgery on
in-hospital mortality. The third model added the BUN level
at baseline. We did not include this variable in initial
modeling, because it was collected for only 673 of the 1,163
patients. The same is true for coronary anatomy because
coronary angiography was not performed in all patients;
data were available in only 692 patients. All variables with a
final p-value of #0.05 were retained in the multivariable
models. All analyses were conducted using SAS software
(SAS Institute, version 6.12, Cary, North Carolina).
RESULTS
Baseline characteristics. Diabetes status was recorded in
1,163 of the 1,190 Registry patients; 379 (33%) patients had
diabetes and 784 patients did not (Table 1). Age, height and
weight did not differ by diabetic status; neither did the
prevalence of prior bypass surgery, prior angioplasty, current
smoking or hyperlipidemia. Diabetics were significantly less
likely to be white and significantly more likely to be female
or Hispanic and to have a history of MI, congestive heart
failure, hypertension or peripheral vascular disease. Renal
insufficiency was present in a significantly greater proportion
of diabetics; both the median BUN and median serum
creatinine were higher in this group.
Clinical findings. Table 2 shows differences in infarct-
related findings. Diabetics were significantly less likely to
have Q waves in two or more leads. The median highest
total CK was significantly lower in diabetics. There were no
significant differences in MI location by ECG, but new left
bundle-branch block was significantly more common in
diabetics. The time from onset of MI to development of CS
did not differ significantly between groups.
There was no significant difference in the rate of chest
pain between diabetics and nondiabetics. Diabetics under-
went coronary angiography less often than nondiabetics
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
BARI 5 Bypass Angioplasty Revascularization
Investigation
BUN 5 blood urea nitrogen
CK(-MB) 5 creatine kinase (-MB)
CS 5 cardiogenic shock
GUSTO-I 5 Global Utilization of Streptokinase and
TPA (alteplase) for Occluded coronary
arteries (trial)
LV 5 left ventricular, left ventricle
MR 5 mitral regurgitation
RV 5 right ventricular
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Occluded Coronaries for cardiogenic
shocK? (trial)
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(56% vs. 65%, p 5 0.006). There was no significant
difference in culprit coronary artery, or in the rate of left
main stenosis that was $50% (Table 2). Diabetics had
significantly more two-vessel and three-vessel coronary
artery disease (p , 0.001). Left ventricular ejection fraction
(total n 5 459) was significantly lower in diabetics (p 5
0.006).
Of the shock-related clinical variables measured (Table
3), aortic stenosis, other significant valvular disease and
other causes for shock were significantly more frequent in
diabetics (p , 0.05). The rates of severe hemorrhage,
mechanical complications, isolated RV CS, dilated cardio-
myopathy and anoxic brain damage were not significantly
different in the two groups. The hemodynamic variables
measured closest to shock likewise did not vary significantly
between diabetics and nondiabetics, with the exception of
diastolic blood pressure (BP); but the 1 mm Hg difference is
not clinically significant.
Treatment. Diabetics were less likely to receive thrombo-
lytic agents (p 5 0.002) (Table 4). When the rates of
attempted angioplasty and bypass surgery were assessed
separately, they did not differ by diabetic status; but when
the rates were combined, the rate of attempted revascular-
ization was significantly lower in diabetics (40% vs. 49%,
p 5 0.008). Diabetics received mechanical ventilation more
often (p , 0.001). The rates of balloon-pump use and
right-heart catheterization were not significantly different.
In-hospital mortality. Unadjusted in-hospital mortality
was 67% in the diabetics versus 58% in the nondiabetics
(p 5 0.007). In a logistic regression model that adjusted for
significant baseline differences (diastolic BP at shock onset,
Hispanic race, severe systemic illness), diabetes mellitus
remained an independent risk factor for in-hospital mortal-
ity (odds ratio [OR], 1.47; 95% confidence interval [CI],
1.10 to 1.96; p 5 0.009). For patients who underwent
angioplasty only (n 5 318), in-hospital survival rates were
48% in diabetics vs. 56% in nondiabetics (p 5 0.217). For
patients who underwent bypass surgery (n 5 216, which
includes 36 patients who underwent both angioplasty and
bypass surgery), survival rates were 65% in diabetics and
64% in nondiabetics (p 5 0.875). In a second model that
adjusted for significant differences in patient and treatment
characteristics (diastolic blood pressure at shock onset,
severe systemic illness, thrombolysis, and angioplasty or
bypass surgery), diabetes remained a borderline independent
predictor of in-hospital mortality (OR, 1.36; 95% CI, 1.00
to 1.84; p 5 0.051). When baseline BUN (collected on only
673 patients) was added to the model that included patient
and treatment variables, diabetes was no longer a significant,
independent predictor of in-hospital mortality (OR, 1.23;
95% CI, 0.85 to 1.78; p 5 0.268).
The survival benefit in diabetics selected for revascular-
ization (55% vs. 19% for nonrevascularized patients) was
similar to that of nondiabetics (59% vs. 25%; test for
interaction, p 5 0.303) (Fig. 1). In the randomized
SHOCK Trial, diabetics and nondiabetics derived similar
benefit from emergency early revascularization (Table 5).
DISCUSSION
Diabetics comprise a significant portion of patients (about
25%) both in MI trials that have assessed the incidence of
CS (20) and in a large observational study of CS (21,22).
Small series of revascularization attempts in CS have not
specified the number of diabetics (23–25), precluding meta-
analysis for the significance of diabetes. The large number of
diabetics in the SHOCK Trial Registry shows that the
unadjusted in-hospital mortality of diabetics with CS is
significantly higher than that of nondiabetics—but much
less so after adjustment for baseline and treatment differ-
ences. More importantly, diabetic patients appeared to
derive a benefit from revascularization similar to that of
shock patients without diabetes, consistent with the overall
results of the SHOCK Trial (10).
Prognostic implications. The poorer prognosis of AMI in
diabetics is not explained by a larger infarct size (26).
Diabetics were significantly less likely to have Q waves in
two or more leads on the index MI ECG or to have
ST-segment elevation after the index MI. The median
highest total CK was significantly lower in diabetics. The
higher rate of many baseline cardiovascular abnormalities in
Table 1. Baseline Demographic and Clinical Characteristics of
AMI Patients With CS
Diabetics
(n 5 379)
Nondiabetics
(n 5 784) p Value
Age (yrs) 69 6 11 69 6 12 0.915
Age $65 years 67% 66% 0.644
Female gender 49% 36% , 0.001
Height (n 5 195) (n 5 408)
(in.) 65.9 6 3.8 66.3 6 4.3 0.178
Weight (n 5 232) (n 5 486)
(lbs) 165 6 35 164 6 36 0.756
Race
White 77% 85% 0.001
African American 6% 4% 0.169
Hispanic 9% 5% 0.002
History of infarction 43% 34% 0.002
History of hypertension 66% 47% , 0.001
Congestive heart failure 30% 15% , 0.001
History of bypass surgery 9% 10% 0.668
History of angioplasty 7% 6% 0.431
Current smoking 49% 50% 0.735
Hyperlipidemia (n 5 178) (n 5 412)
40% 43% 0.716
History of peripheral
vascular disease
(n 5 229) (n 5 526)
28% 13% , 0.001
Severe systemic illness* 10% 6% 0.033
History of renal
insufficiency
18% 8% , 0.001
Blood urea nitrogen (n 5 260) (n 5 536)
(mg/dL) 32 6 24 27 6 21 , 0.001
Serum creatinine (n 5 260) (n 5 544)
(mg/dL) 3.2 6 5.3 3.6 6 7.8 0.022
*Life-shortening, noncardiac disease.
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the SHOCK Trial Registry diabetics, including prior MI
and congestive heart failure, and the presence of more
extensive coronary artery disease and poorer LV ejection
fraction, may explain the poorer prognosis. Another possible
explanation for the higher mortality of diabetics is that they
were less likely to undergo thrombolysis or to undergo
Table 2. Characteristics of the Index MI in Patients With CS
Diabetics
(n 5 379)
Nondiabetics
(n 5 784) p Value
Q waves in $2 leads 25% 36% , 0.001
New left bundle-branch block 14% 7% , 0.001
Chest pain 80% 84% 0.098
ST-segment elevation in $2 leads 68% 73% 0.085
Location of infarction
Anterior 52% 56% 0.283
Inferior 49% 45% 0.315
Posterior 17% 21% 0.273
Lateral 31% 33% 0.616
Apical 11% 11% 0.832
Multiple 45% 52% 0.061
Non-ST-segment elevation MI* 23% 20% 0.252
Median hours from MI onset to shock
onset (25th to 75th percentile)
8.2 (1.9, 25.0) 6.7 (1.8, 20.8) 0.252
Time from MI to shock ,6 h 42% 45% 0.430
Highest total creatine kinase (IU/L) 1358 (496, 3,240) 1981 (727, 4,000) , 0.001
Ratio, highest creatine kinase/ULN 7.2 (2.3, 15.9) 9.6 (3.4, 19.7) 0.001
Left main stenosis $50% (n 5 203) (n 5 473)
13% 16% 0.415
Number of diseased vessels (n 5 206) (n 5 486) , 0.001
None 1% 1%
One 14% 26%
Two 26% 23%
Three 59% 51%
Culprit Artery (n 5 155) (n 5 384) 0.421
Left anterior descending 41% 41%
Circumflex 18% 15%
Right 29% 30%
Left main 3% 6%
Bypass graft 9% 7%
Left ventricular ejection fraction at any (n 5 162) (n 5 297)
time during hospital stay 30 6 13 34 6 14 0.006
*Includes old left bundle-branch block.
MI 5 myocardial infarction; ULN 5 upper limit of normal.
Table 3. Etiology, Complications and Hemodynamic Measures of CS in AMI
Diabetics
(n 5 379)
Nondiabetics
(n 5 784) p Value
Severe hemorrhage 1% 2% 0.071
Mechanical complications of MI* 11% 13% 0.217
Isolated right ventricular shock 3% 3% 0.861
Other cause of shock 6% 3% 0.036
Valvular† 5% 2% 0.045
Dilated cardiomyopathy 5% 4% 0.353
Tamponade 1% 2% 0.335
Anoxic brain damage 5% 3% 0.095
Heart rate (beats/min) 95 6 25 96 6 26 0.361
Systolic blood pressure (mm Hg) 88 6 21 88 6 23 0.747
Diastolic blood pressure (mm Hg) 52 6 15 53 6 18 0.040
Pulmonary capillary wedge pressure (mm Hg) (n 5 237) (n 5 487) 0.149
24 6 8.7 23 6 8.3
Cardiac index (L/min/m2) (n 5 182) (n 5 369) 0.272
2.0 6 0.7 2.1 6 0.8
*Ventricular septal rupture and acute severe mitral regurgitation; †Aortic stenosis or other severe valvular disease. Hemodynamic
values were recorded on support measures.
AMI 5 acute myocardial infarction; CS 5 cardiogenic shock.
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attempted revascularization with angioplasty, bypass sur-
gery, or both. However, diabetic status remained marginally
significant after adjusting for baseline and treatment differ-
ences.
An intriguing possible explanation for the poorer out-
comes of diabetic patients may be metabolic abnormalities
related to the degree and method of glycemic control both
before and after AMI. The Diabetes mellitus, Insulin-
Glucose infusion in Acute Myocardial Infarction
(DIGAMI) study showed that the admission blood-glucose
level was an independent predictor of mortality over an
average 3.4-year follow-up period and that intensive insulin
treatment reduced long-term mortality even among patients
with hyperglycemia at baseline (27).
Reperfusion strategies. Studies of revascularization in CS
have included diabetics, but the number of patients has been
too small to comment on the significance of diabetes in CS
(4,28–30). Large trials show that a history of diabetes is
associated with a poorer prognosis after MI in patients
treated with thrombolytic agents (12,31,32). This implies a
greater potential for absolute benefit from thrombolysis for
AMI in diabetics. Yet, diabetics may be less likely to receive
thrombolytic therapy (33). In subgroup analyses of random-
ized trials, diabetics with MI have been shown to derive a
clinical benefit from either thrombolysis or primary angio-
plasty similar to that of patients without diabetes, and a
similar early relative advantage from primary angioplasty
versus thrombolysis (13,16). Some physicians may be reluc-
tant to give thrombolytic agents to diabetics, because of
concern about ocular hemorrhage in those with diabetic
retinopathy, but this concern has been shown to be unjus-
tified (34).
In the randomized BARI trial (17), diabetics with mul-
tivessel disease randomized to bypass surgery had signifi-
cantly better five-year outcomes than did those randomized
to angioplasty. Of note, no such treatment difference was
seen in the BARI Registry, in which the type of revascu-
larization procedure was determined by the attending phy-
sician (18). This difference may reflect selection bias rather
than true differences in treatment effect. Although these
findings cannot be extrapolated to the SHOCK Trial
Registry diabetics, those who underwent angioplasty, bypass
surgery, or both, derived a survival benefit similar to that of
the SHOCK Trial Registry nondiabetics who underwent
these revascularization procedures. This beneficial in-
hospital effect of revascularization in the large Registry
population of diabetics supports the randomized Trial
finding that diabetics and nondiabetics derived similar
survival benefit from early revascularization at six-month
and one-year follow-up.
Study limitations. This subgroup analysis of an observa-
tional Registry database carries the inherent dangers of
selection bias and small sample sizes. However, it does
reflect the treatment of these patients in everyday practice.
Renal insufficiency was present in a significantly greater
proportion of diabetics. The third logistic regression model
attempted to address this by including baseline BUN. This
was possible in only 673 of 1,163 patients. In this subset of
patients, diabetes was not significantly associated with
in-hospital mortality.
The lower ejection fraction, lower incidence of single-
vessel disease, and higher incidence of two- and three-vessel
Figure 1. Survival benefit in diabetics (black bars) and nondiabetics (white bars), overall and by selection for revascularization by angioplasty or bypass
surgery. *Includes 36 patients who underwent both angioplasty and bypass surgery.
Table 4. In-hospital Treatment of AMI Patients With CS
Diabetics
(n 5 379)
Nondiabetics
(n 5 784) p Value
Intra-aortic balloon pump 53% 55% 0.415
Ventilator 83% 73% , 0.001
Thrombolytic agent 28% 37% 0.002
Right-heart catheterization 68% 66% 0.596
Coronary Angiography 56% 65% 0.006
Revascularization attempted 40% 49% 0.008
Angioplasty attempted 28% 32% 0.174
Bypass surgery attempted 16% 20% 0.108
Abbreviations are the same as in Table 3.
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disease may well affect survival, but many patients in this
study did not undergo angiography.
Conclusions. Diabetics with CS complicating AMI had a
higher-risk profile than nondiabetics. However, their in-
hospital survival was only marginally lower than that of
nondiabetics after adjustment for these risk factors. More-
over, diabetics appeared to derive a benefit from revascular-
ization similar to that of nondiabetics with CS in both the
SHOCK Trial Registry and the randomized SHOCK Trial.
Despite their higher-risk profile, diabetics should be
strongly considered for early revascularization for CS com-
plicating AMI.
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